Gamunex-C

Manufacturer: Talecris Biotherapeutics

Gamunex-C is a leading IG (immune globulin) therapy. Gamunex-C routes of administration include both intravenous and subcutaneous delivery. The intravenous delivery mode is approved to treat primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and idiopathic thrombocytopenic purpura (ITP). The subcutaneous mode is approved to treat only PI.

GAMUNEX-C is an IGIV therapy manufactured using plasma from healthy donors collected in centers across the United States and is indicated for:

• Patients with CIDP: when the body's immune system mistakes myelin—the protective covering around nerve fibers—as foreign and attacks it, GAMUNEX-C provides healthy antibodies to block the immune and inflammatory processes that attack and destroy myelin
• Patients with PI: when the body lacks the healthy antibodies needed to fight off infections caused by viruses and bacteria, GAMUNEX-C provides those healthy antibodies
• Patients with ITP: when the body makes antibodies that destroy platelets, the cells found in the blood that control bleeding, GAMUNEX-C provides healthy antibodies to bring the platelet count back to a healthier level

If you have CIDP, PI, or ITP and are being treated with IGIV, you will receive an infusion of IGIV on a regularly scheduled basis as determined by your doctor. It will most likely be given to you through a vein in your arm at a doctor's office, hospital, or infusion center. You may also be able to arrange to have your infusion at home.

Gamunex-C Product Insert

http://www.gamunex-c.com/